A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Vertex is also testing the drug as a treatment ... The drug also appears to have far milder side effects than opioids. Its efficacy, however, may leave something to be desired.

Those chemical interactions also give rise to opioids' addictive effects. Vertex's drug works differently, blocking proteins that trigger pain signals that are later sent to the brain.

which could lead to adverse effects. The drug comes from a pain research program that began at Vertex about 25 years ago. FDA approval of Journavx is based on the results of two Phase 3 studies ...

Those chemical interactions also give rise to opioids' addictive effects. Vertex's drug works differently, blocking proteins that trigger pain signals that are later sent to the brain. "In trying to ...

Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...

Those chemical interactions also give rise to opioids' addictive effects. Vertex’s drug works differently, blocking proteins that trigger pain signals that are later sent to the brain.

Patients may report side effects to the FDA at 1-800-FDA-1088. Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with ...

(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...

Vertex's total revenues for Q4 2024 were $ ... our expectations regarding the effects of the Capped Call Transactions and regarding actions of the Option Counterparties and/or their respective ...